After a hiatus, CRND is delighted to launch Clinical Translational Seminar Series 2020-2021.

This Series is part of the curricular content for BIOS 60565 Topics in Rare and Neglected Diseases and BIOS 60550 Topics in Pathobiology. The goal is to provide a forum to discuss topics that impact the lives of patients with rare and neglected diseases in the 21st century. We hope to learn about ground breaking solutions as we train students and fellows as next generation leaders.

We start with Covid-19. The pandemic has affected essentially all countries and peoples including our campus. However, less well known is that infection by SARS-CoV-2, the causative agent of Covid-19, is linked to induction of rare syndromes. Many patients with rare and neglected diseases are at greater risk of infection and/or severe disease. In addition, because Covid-19 has placed high demand on existing hospital and clinical capacities, doctor’s visits and procedures needed by rare and neglected disease patients have been frequently cancelled and/or delayed. This has increased the burden of health management and treatment for these patients, who already have high unmet need. There is poor understanding of the impact of Covid-19 on this vulnerable population, despite the fact that 1 in 10 people in the US and world-wide suffer from a rare and neglected disease. Hence serving their needs is a public health priority.

CTSS 21 is a VIRTUAL series, held Mondays from 4.00-5.30 pm.

Schedule Clinical Translational Seminar Series 2020-2021. Mondays 4.00-5.30 pm

August 31st

Dr. Joseph DeRisi, Professor of Biochemistry and Biophysics, University of California, San Francisco; Co-President, Chan Zuckerberg Biohub.

“Rapid Deployment of SARS-CoV-2 testing: the CLIAHUB”

September 14th

Dr. Anne Rowley, Professor of Pediatrics and Microbiology/Immunology, Northwestern University Feinberg School of Medicine

"The Differing Pathogenesis of Kawasaki Disease and Covid-19-Associated Multisystem Inflammatory Syndrome"

October 12th

Dr. Stanley Perlman, Professor of Microbiology Immunology and of Pediatrics, Stinksi Chair in Virology. University of Iowa.

“Models for Covid-19 Pathogenesis Vaccination and Treatment”

November 2nd

Dr. Andrew Mesecar, Head, Dept. Biochemistry, Walther Professor & Deputy Director, Purdue Cancer Center, Purdue University.

"SARS-CoV-2 protease inhibitors as drugs for treating COVID-19"